O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma
Drug Resistance Updates · 2024
DOI: 10.1016/j.drup.2024.101150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024. Verfasst von Xiangbo Zeng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Apoptosis, Kidney Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Receptor interacting protein kinase 1 (RIPK1) has emerged as a key regulatory molecule that influences the balance between cell death and cell survival. Under external stress, RIPK1 determines whether a cell undergoes RIPK-dependent apoptosis (RDA) or survives by activating NF-κB signaling. However, the role and mechanisms of RIPK1 on sunitinib sensitivity in renal cell carcinoma (RCC) remain elusive. In this study, we demonstrated that the O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) of RIPK1 induces sunitinib resistance in RCC by inhibiting RDA. O-GlcNAc transferase (OGT) specifically interacts with RIPK1 through its tetratricopeptide repeats (TPR) domain and facilitates RIPK1 O-GlcNAcylation. The O-GlcNAcylation of RIPK1 at Ser331, Ser440 and Ser669 regulates RIPK1 ubiquitination and the formation of the RIPK1/FADD/Caspase-8 complex, thereby inhibiting sunitinib-induced RDA in RCC. Site-specific depletion of O-GlcNAcylation on RIPK1 affects the formation of the RIPK1/FADD/Caspase 8 complex, leading to increased sunitinib sensitivity in RCC. Our data highlight the significance of aberrant RIPK1 O-GlcNAcylation in the development of sunitinib resistance and indicate that targeting RIPK1 O-GlcNAcylation could be a promising therapeutic strategy for RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
- Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510000, China.
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
- Department of Urology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510799, China.
- Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- Southern Medical University
Zitieren
APA
Zeng, X., Chen, Z., Zhu, Y., Liu, L., Zhang, Z., Xiao, Y., Wang, Q., Pang, S., Zhao, F., Xu, B., Leng, M., Liu, X., Hu, C., Zeng, S., Li, F., Xie, W., Tan, W., & Zheng, Z. (2024). O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2024.101150
Vancouver
Zeng X, Chen Z, Zhu Y, Liu L, Zhang Z, Xiao Y, et al. O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma. Drug Resistance Updates. 2024. doi:10.1016/j.drup.2024.101150
BibTeX
@article{Zeng2024,
author = {Zeng, Xiangbo and Chen, Zhiliang and Zhu, Yuanchao and Liu, Lei and Zhang, Zhiyong and Xiao, Yongyuan and Wang, Qiong and Pang, Shiyu and Zhao, Fengjin and Xu, Bihong and Leng, Mengxin and Liu, Xiaocen and Hu, Chenxi and Zeng, Siying and Li, Fei and Xie, Wenlian and Tan, Wanlong and Zheng, Zaosong},
title = {O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma},
journal = {Drug Resistance Updates},
year = {2024},
doi = {10.1016/j.drup.2024.101150}
}
EUVIMED